CATALYSIS CAPITAL PARTNERS is pleased to announce that it acted as the exclusive financial advisor to Diagnoplex SA in connection with the signing of a collaborative agreement with Unilabs SA for the European commercialization of Colox®. Financial terms were not disclosed.
Diagnoplex SA (Lausanne, Switzerland) is a developer of molecular diagnostics for colorectal cancer. The company’s lead product, Colox®, is a convenient and minimally invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox® has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox® leverages the information from nucleic acids carried by peripheral blood mononuclear cells. Peripheral blood mononuclear cells are instrumental for tumour-host interactions, the so-called “host response”, and are involved at the earliest stages of tumour formation. Diagnoplex’s ability to screen for the host response enables it to detect colorectal cancer risk at early and even pre-cancerous stage. Colox® will initially be available in Switzerland and Sweden. For more information, visit: www.diagnoplex.com
Unilabs SA (Geneva, Switzerland) is a leading diagnostic services company. The company operates more than 120 laboratories and 44 radiology units in Denmark, Finland, France, Italy, Norway, Portugal, Russia, Spain, Sweden, Switzerland, and the United Kingdom. Customers include public and private healthcare providers, county councils, the general public, insurance companies, the pharmaceutical industry and CROs. Unilabs supplies medical laboratory services within: laboratory medicine, genetic testing, medical imaging, cellular pathology, reproductive medicine, drug development services and clinical trials. For more information, visit www.unilabs.com
CATALYSIS Advises Life Science Innovators. Based in London, United Kingdom, CATALYSIS CAPITAL PARTNERS provides financial and strategic advice to industry leaders and emerging growth companies in diagnostics, medical devices, biotechnology and drug delivery. CATALYSIS brings a unique combination of broad transactional experience, extensive industry expertise and senior-level focus to each client relationship. CATALYSIS CAPITAL PARTNERS is authorized and regulated by the Financial Conduct Authority (FCA) UK.